See more : CorVel Corporation (CRVL) Income Statement Analysis – Financial Results
Complete financial analysis of Titan Pharmaceuticals, Inc. (TTNP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Titan Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Silgo Retail Limited (SILGO.NS) Income Statement Analysis – Financial Results
- Metalgráfica Iguaçu S.A. (MTIG4.SA) Income Statement Analysis – Financial Results
- Dynex Energy S.A. (MLDYX.PA) Income Statement Analysis – Financial Results
- Sagicor Financial Company Ltd. (SFC.TO) Income Statement Analysis – Financial Results
- PT Jasuindo Tiga Perkasa Tbk (JTPE.JK) Income Statement Analysis – Financial Results
Titan Pharmaceuticals, Inc. (TTNP)
About Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 184.00K | 60.00K | 1.53M | 4.84M | 3.61M | 5.91M | 215.00K | 15.07M | 1.67M | 3.65M | 10.48M | 7.12M | 4.07M | 10.09M | 79.00K | 70.00K | 24.00K | 32.00K | 89.00K | 31.00K | 89.00K | 2.89M | 4.57M | 1.88M | 300.00K | 100.00K | 17.50M | 300.00K | 100.00K |
| Cost of Revenue | 112.00K | 196.00K | 199.00K | 472.00K | 1.29M | 538.00K | 9.65M | 6.13M | 4.68M | 4.08M | 8.31M | 10.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -196.00K | -400.00K | -300.00K | -400.00K | -500.00K | -300.00K |
| Gross Profit | 72.00K | -136.00K | 1.33M | 4.37M | 2.32M | 5.37M | -9.43M | 8.94M | -3.00M | -429.00K | 2.17M | -3.49M | 4.07M | 10.09M | 79.00K | 70.00K | 24.00K | 32.00K | 89.00K | 31.00K | 89.00K | 2.89M | 4.57M | 2.08M | 700.00K | 400.00K | 17.90M | 800.00K | 400.00K |
| Gross Profit Ratio | 39.13% | -226.67% | 86.96% | 90.24% | 64.33% | 90.90% | -4,387.44% | 59.34% | -179.77% | -11.77% | 20.72% | -49.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 110.43% | 233.33% | 400.00% | 102.29% | 266.67% | 400.00% |
| Research & Development | 1.91M | 4.76M | 5.69M | 5.92M | 7.24M | 7.48M | 9.65M | 6.13M | 4.68M | 4.08M | 8.31M | 10.61M | 11.21M | 12.86M | 2.46M | 16.24M | 12.24M | 11.62M | 17.77M | 20.42M | 22.26M | 29.82M | 23.34M | 16.74M | 9.40M | 7.80M | 18.80M | 5.60M | 0.00 |
| General & Administrative | 5.55M | 6.03M | 4.99M | 5.80M | 5.40M | 0.00 | 5.07M | 4.60M | 3.76M | 3.05M | 3.06M | 4.88M | 3.37M | 3.26M | 3.44M | 9.76M | 6.21M | 4.86M | 5.37M | 5.24M | 5.11M | 5.08M | 5.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.55M | 6.03M | 4.99M | 5.80M | 11.93M | 6.87M | 5.07M | 4.60M | 3.76M | 3.05M | 3.06M | 4.88M | 3.37M | 3.26M | 3.44M | 9.76M | 6.21M | 4.86M | 5.37M | 5.24M | 5.11M | 5.08M | 5.38M | 4.07M | 2.80M | 3.70M | 6.50M | 5.30M | 9.50M |
| Other Expenses | -183.00K | -497.00K | -84.00K | 1.72M | 17.00K | -6.00K | -55.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 0.00 | 0.00 | 0.00 | 759.00K | 3.90M | 0.00 | 0.00 | 196.00K | 400.00K | 300.00K | 400.00K | 500.00K | 300.00K |
| Operating Expenses | 7.28M | 10.30M | 10.68M | 11.72M | 19.17M | 13.64M | 14.72M | 10.72M | 8.43M | 7.12M | 11.37M | 15.49M | 14.57M | 16.12M | 5.89M | 25.99M | 18.46M | 16.48M | 23.14M | 25.65M | 27.37M | 34.90M | 28.72M | 21.01M | 12.60M | 11.80M | 25.70M | 11.40M | 9.80M |
| Cost & Expenses | 7.46M | 10.30M | 10.88M | 12.19M | 20.46M | 14.18M | 14.72M | 10.72M | 8.43M | 7.12M | 11.37M | 15.49M | 14.57M | 16.12M | 5.89M | 25.99M | 18.46M | 16.48M | 23.14M | 25.65M | 27.37M | 34.90M | 28.72M | 20.81M | 12.20M | 11.50M | 25.30M | 10.90M | 9.50M |
| Interest Income | 5.00K | 53.00K | 1.00K | 769.00K | 967.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 717.00K | 570.00K | 673.00K | 1.28M | 4.22M | 6.76M | 5.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.00K | 769.00K | 967.00K | 887.00K | 369.00K | 37.00K | 0.00 | 0.00 | 1.57M | 4.86M | 6.43M | 678.00K | 6.00K | 470.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00M | 1.90M |
| Depreciation & Amortization | 112.00K | 196.00K | 221.00K | 292.00K | 244.00K | 380.00K | 417.00K | 377.00K | 358.00K | 353.00K | 107.00K | 17.00K | 32.00K | 85.00K | 169.00K | 210.00K | 288.00K | 389.00K | 405.00K | 466.00K | 439.00K | 1.57M | 647.00K | 196.00K | 400.00K | 300.00K | 400.00K | 500.00K | 300.00K |
| EBITDA | -7.17M | -10.04M | -9.13M | -7.06M | -6.28M | -7.88M | -14.09M | 4.72M | -6.40M | -3.12M | -784.00K | -8.35M | -10.51M | -6.07M | -5.65M | -25.22M | -18.15M | -16.06M | -22.65M | -25.54M | -26.84M | -30.43M | -23.50M | -18.74M | -11.50M | -11.20M | -7.40M | -10.00M | -9.10M |
| EBITDA Ratio | -3,894.02% | -16,731.67% | -641.81% | -110.42% | -496.70% | -135.65% | -6,839.07% | 26.32% | -112.57% | -115.03% | -123.60% | -117.37% | -300.07% | -57.55% | -7,064.56% | -35,357.14% | -76,187.50% | -50,159.38% | -25,466.29% | -77,738.71% | -25,786.52% | -1,038.52% | -512.38% | -730.21% | -3,800.00% | -12,000.00% | -92.00% | -3,266.67% | -8,700.00% |
| Operating Income | -7.28M | -10.24M | -9.35M | -7.35M | -16.84M | -8.26M | -14.50M | 4.34M | -6.76M | -3.48M | -891.00K | -8.37M | -10.51M | -6.03M | -5.82M | -25.92M | -18.43M | -16.45M | -23.05M | -26.38M | -31.17M | -32.00M | -24.15M | -18.93M | -11.90M | -11.40M | -7.80M | -10.60M | -9.40M |
| Operating Income Ratio | -3,954.89% | -17,058.33% | -612.98% | -151.94% | -466.46% | -139.81% | -6,745.12% | 28.83% | -404.49% | -95.31% | -8.50% | -117.61% | -258.26% | -59.69% | -7,360.76% | -37,028.57% | -76,804.17% | -51,396.88% | -25,900.00% | -85,096.77% | -35,026.97% | -1,106.60% | -528.22% | -1,007.13% | -3,966.67% | -11,400.00% | -44.57% | -3,533.33% | -9,400.00% |
| Total Other Income/Expenses | 1.71M | 29.00K | 578.00K | -56.00K | 386.00K | -759.00K | 195.00K | 792.00K | -4.52M | 1.07M | 10.60M | -6.81M | -4.70M | -809.00K | -71.00K | 490.00K | 786.00K | 710.00K | 589.00K | 376.00K | 1.29M | 3.82M | 6.69M | -5.01M | -100.00K | 999.00K | 8.70M | -400.00K | -400.00K |
| Income Before Tax | -5.57M | -10.21M | -8.78M | -7.41M | -16.46M | -9.02M | -14.31M | 5.14M | -11.28M | -2.40M | 9.71M | -15.18M | -15.20M | -6.83M | -5.88M | -25.43M | -17.65M | -15.74M | -22.46M | -26.00M | -29.89M | -28.18M | -17.46M | -23.94M | -12.00M | -10.50M | 900.00K | -10.90M | -9.80M |
| Income Before Tax Ratio | -3,026.63% | -17,010.00% | -575.10% | -153.10% | -455.77% | -152.65% | -6,654.42% | 34.09% | -674.99% | -65.91% | 92.65% | -213.29% | -373.72% | -67.71% | -7,443.04% | -36,328.57% | -73,529.17% | -49,178.13% | -25,238.20% | -83,883.87% | -33,583.15% | -974.48% | -381.98% | -1,273.62% | -4,000.00% | -10,500.00% | 5.14% | -3,633.33% | -9,800.00% |
| Income Tax Expense | 0.00 | -29.00K | -662.00K | 13.32M | -369.00K | -1.65M | -250.00K | -792.00K | 4.52M | -1.07M | -10.60M | 4.86M | 4.70M | 809.00K | 71.00K | 960.00K | -786.00K | -710.00K | -589.00K | 383.00K | 2.61M | -3.82M | -6.69M | -146.00K | -600.00K | -800.00K | -8.40M | 2.30M | 2.30M |
| Net Income | -5.57M | -10.18M | -8.11M | -20.73M | -16.09M | -9.02M | -14.31M | 5.14M | -11.28M | -2.40M | 9.71M | -15.18M | -15.20M | -6.83M | -5.89M | -25.43M | -17.65M | -15.74M | -22.46M | -26.00M | -29.89M | -28.18M | -17.46M | -18.79M | -11.30M | -10.60M | 600.00K | -12.90M | -11.70M |
| Net Income Ratio | -3,026.63% | -16,961.67% | -531.72% | -428.44% | -445.56% | -152.65% | -6,654.42% | 34.09% | -674.99% | -65.91% | 92.65% | -213.29% | -373.72% | -67.71% | -7,450.63% | -36,328.57% | -73,529.17% | -49,178.13% | -25,238.20% | -83,883.87% | -33,583.15% | -974.48% | -381.98% | -999.36% | -3,766.67% | -10,600.00% | 3.43% | -4,300.00% | -11,700.00% |
| EPS | -7.41 | -15.15 | -16.68 | -109.88 | -12.60K | -47.59 | -121.48 | 44.71 | -101.24 | -25.36 | 117.00 | -227.70 | -253.71 | -114.20 | -99.66 | -14.37 | -406.32 | -411.06 | -681.41 | -820.39 | -1.06K | -1.01K | -626.56 | -726.84 | -694.36 | -800.60 | 39.60 | -1.03K | -1.53K |
| EPS Diluted | -7.41 | -15.15 | -16.68 | -109.88 | -12.60K | -47.59 | -121.34 | 36.01 | -101.24 | -25.35 | 95.40 | -225.96 | -249.23 | -114.20 | -99.66 | -14.37 | -406.32 | -411.06 | -681.41 | -820.39 | -1.06K | -1.01K | -626.56 | -726.84 | -694.36 | -800.60 | 39.60 | -1.03K | -1.53K |
| Weighted Avg Shares Out | 752.00K | 671.70K | 486.50K | 188.65K | 1.28K | 189.60K | 117.78K | 115.21K | 111.40K | 94.76K | 82.93K | 66.67K | 59.92K | 59.85K | 59.06K | 1.77M | 43.43K | 38.28K | 32.96K | 31.70K | 28.19K | 27.92K | 27.87K | 25.85K | 16.27K | 13.24K | 15.15K | 12.52K | 7.64K |
| Weighted Avg Shares Out (Dil) | 752.00K | 671.70K | 486.50K | 188.65K | 1.28K | 189.60K | 117.91K | 119.21K | 111.40K | 94.78K | 83.49K | 67.18K | 61.00K | 59.85K | 59.06K | 1.77M | 43.43K | 38.28K | 32.96K | 31.70K | 28.19K | 27.92K | 27.87K | 25.85K | 16.27K | 13.24K | 15.15K | 12.52K | 7.64K |
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales Company to receive $2 million in upfront payments, with the potential...
Which Industries Are Penny Stocks Investors Watching Right Now
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What to Know About Buying Penny Stocks on July 8th
Here's what you need to know about trading penny stocks on July 8th The post What to Know About Buying Penny Stocks on July 8th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving
Penny stocks to watch with news The post Penny Stocks To Watch: Why KRKR, RMED, TYME, TTNP & ENDP Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Titan Pharmaceuticals Raises $5.5M Via Equity
Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model, has...
Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K
SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission...
TTNP Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is trading at over 15% pre-market. This is why it happened.
Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being...
Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $9.7 million of its common stock in a...
Source: https://incomestatements.info
Category: Stock Reports